Novel Cancer-Targeting Virus Therapy Shows Efficacy in Early-Stage Trial

August 31, 2011
Anna Azvolinsky

Scientists at Jennerex, Inc. in San Francisco, and collaborators from University of Pennsylvania and the University of Ottawa in Canada have just engineered a poxvirus, JX-594, to selectively replicate in tumor cells that have an activated EGFR/ Ras pathway, but not in normal tissue.